Takara Bio Of Japan, University Join To Make Protein-Based Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Japan's Takara Bio and Kyoto Prefectural University of Medicine plan to develop an immunotherapy drug to treat cancer by relying on a single protein. Researchers at the institutions plan to use the RetroNectin recombinant protein. The researchers believe the treatment could extend the life of lymph cells in cancer patients. No estimation was provided about sales expectations or forecast of marketing approval. (Click here for more - a subscription may be required